A new trading day began on Tuesday, with Idexx Laboratories, Inc. (NASDAQ: IDXX) stock price down -0.28% from the previous day of trading, before settling in for the closing price of $492.43. IDXX’s price has ranged from $372.50 to $583.39 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 10.69%. Meanwhile, its annual earnings per share averaged 10.00%. With a float of $81.69 million, this company’s outstanding shares have now reached $83.03 million.
Let’s determine the extent of company efficiency that accounts for 11000 employees.
Idexx Laboratories, Inc. (IDXX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Diagnostics & Research Industry. The insider ownership of Idexx Laboratories, Inc. is 1.08%, while institutional ownership is 90.32%. The most recent insider transaction that took place on May 17 ’24, was worth 108,160. In this transaction Director of this company sold 200 shares at a rate of $540.80, taking the stock ownership to the 161 shares. Before that another transaction happened on Mar 06 ’24, when Company’s Executive Vice President sold 8,104 for $558.44, making the entire transaction worth $4,525,596. This insider now owns 10,711 shares in total.
Idexx Laboratories, Inc. (IDXX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 10.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to 18.76% growth over the previous five years of trading.
Idexx Laboratories, Inc. (NASDAQ: IDXX) Trading Performance Indicators
Here are Idexx Laboratories, Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.10. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.89. Likewise, its price to free cash flow for the trailing twelve months is 50.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 10.32, a number that is poised to hit 2.89 in the next quarter and is forecasted to reach 12.61 in one year’s time.
Technical Analysis of Idexx Laboratories, Inc. (IDXX)
Looking closely at Idexx Laboratories, Inc. (NASDAQ: IDXX), its last 5-days average volume was 0.63 million, which is a jump from its year-to-date volume of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 14.27%. Additionally, its Average True Range was 12.23.
During the past 100 days, Idexx Laboratories, Inc.’s (IDXX) raw stochastic average was set at 23.94%, which indicates a significant increase from 12.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.40% in the past 14 days, which was lower than the 28.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $505.71, while its 200-day Moving Average is $500.95. However, in the short run, Idexx Laboratories, Inc.’s stock first resistance to watch stands at $494.37. Second resistance stands at $497.68. The third major resistance level sits at $503.35. If the price goes on to break the first support level at $485.38, it is likely to go to the next support level at $479.71. Should the price break the second support level, the third support level stands at $476.40.
Idexx Laboratories, Inc. (NASDAQ: IDXX) Key Stats
With a market capitalization of 40.56 billion, the company has a total of 82,587K Shares Outstanding. Currently, annual sales are 3,661 M while annual income is 845,040 K. The company’s previous quarter sales were 964,100 K while its latest quarter income was 235,580 K.
